Under construction – not a live service
Sign in
Taking people in GermanyPhase 2

Testing AZD8965 Against Placebo in Adults With Idiopathic Pulmonary Fibrosis

Tests AZD8965 against placebo in adults with idiopathic pulmonary fibrosis.

Key facts

Who runs it
AstraZeneca AB
Where
Bonn, Coswig, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover, Heidelberg, Hemer, Leipzig, Luebeck, Marburg, Munich, Stuttgart, and Wuppertal, GermanySee the 16 sitesAlso in 9 other countries, 52 sites
Registry title
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Status
Recruiting
Phase
Phase 2
People taking part
139 people, planned
Started
4 Sept 2026
Expected to end
18 Sept 2028
Type of study
Interventional
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 or older with idiopathic pulmonary fibrosis (IPF), whether or not they take approved antifibrotic medicine.

Age
40 years or older
Sex
All sexes can join.
Disease stage
Idiopathic pulmonary fibrosis (IPF). Lung function: FVC at least 45% predicted of normal, and DLCO corrected for hemoglobin at least 25% predicted of normal.
Earlier treatment
People can be taking locally approved antifibrotic medicine at a stable dose, or not be taking standard treatment for IPF.

Main reasons for not taking part

  • Lung disease other than IPF
  • More emphysema than fibrotic change on the chest HRCT scan
  • Sudden worsening (acute exacerbation) of IPF
  • Lower airway infection that needs treatment
  • Heart failure, a recent heart attack or unstable angina, or a past organ transplant

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥ 40 years
  • IPF diagnosis
  • Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
  • FVC ≥ 45% predicted of normal
  • DLCO corrected for hemoglobin ≥ 25% predicted of normal

Who cannot take part

  • Lower respiratory tract infection requiring treatment
  • Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting
  • Heart failure
  • History of organ transplantation or is likely to receive lung transplantation
  • ILD other than IPF
  • The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
  • Acute exacerbation of IPF

Where in Germany

Also in 9 other countries, 52 sites

  • Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
  • GWT-Tud GmbHCoswig, GermanyTaking people
  • Ruhrlandklinik Westdeutsches Lungenzentrum Am Universitaetsklinikum Essen gGmbHEssen, GermanyTaking people
  • Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
  • Philipps-Universitaet MarburgFulda, GermanyTaking people
  • Justus-Liebig-Universitaet GiessenGiessen, GermanyTaking people
  • University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
  • Klinikum Region Hannover GmbHHanover, GermanyTaking people
  • Thoraxklinik Heidelberg gGmbHHeidelberg, GermanyTaking people
  • Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbHHemer, GermanyTaking people
  • Universitaet LeipzigLeipzig, GermanyTaking people
  • Universitaetsklinikum Schleswig-Holstein AöRLuebeck, GermanyTaking people
  • Zentrum fuer ambulante pneumologische Forschung Marburg GbRMarburg, GermanyTaking people
  • LMU Klinikum Muenchen AöRMunich, GermanyTaking people
  • Robert Bosch Krankenhaus GmbHStuttgart, GermanyTaking people
  • Petrus-KrankenhausWuppertal, GermanyTaking people

About the trial

What the trial wants to find out

To evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)
Plain-language title
Testing AZD8965 Against Placebo in Adults With Idiopathic Pulmonary FibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 11 November 2026.
Record updated
10 November 2026